Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$58,000.

  • Axsome Therapeutics' Cash from Investing Activities rose 35.56% to -$58,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$439,000, marking a year-over-year decrease of 77.73%. This contributed to the annual value of -$270,000 for FY2024, which is 53.61% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Cash from Investing Activities of -$58,000 as of Q3 2025, which was down 346.15% from -$13,000 recorded in Q2 2025.
  • Axsome Therapeutics' Cash from Investing Activities' 5-year high stood at -$7,000 during Q4 2023, with a 5-year trough of -$53.2 million in Q2 2022.
  • Over the past 3 years, Axsome Therapeutics' median Cash from Investing Activities value was -$71,000 (recorded in 2023), while the average stood at -$114,636.
  • Over the last 5 years, Axsome Therapeutics' Cash from Investing Activities had its largest YoY gain of 99.75% in 2023, and its largest YoY loss of 462.12% in 2023.
  • Over the past 4 years, Axsome Therapeutics' Cash from Investing Activities (Quarterly) stood at -$181,000 in 2022, then soared by 96.13% to -$7,000 in 2023, then tumbled by 328.57% to -$30,000 in 2024, then spiked by 35.56% to -$58,000 in 2025.
  • Its last three reported values are -$58,000 in Q3 2025, -$13,000 for Q2 2025, and -$338,000 during Q1 2025.